The present invention relates to a process for the preparation of esomeprazole in amorphous form by spray drying.

The present invention relates to crystalline salts of rasagiline and processes for the preparation thereof. The invention also relates to pharmaceutical compositions comprising the same.

A process for the preparation of (S)-(+)-10, 1 l-dihydro-10-hydroxy-5H-dibenz [b,f] azepine-5-carboxamide of formula (I), its novel intermediates and their use in the synthesis thereof.

The present invention generally relates to a process for the preparation of an antifungal agent posaconazole and to a novel polymorphic form V of antifungal agent posaconazole.

ABSTRACT The present invention provides a process for the preparation of ivabradine and pharmaceutically acceptable salts thereof. The present invention also provides a process for the preparation of amorphous form of ivabradine hydrochloride.

ABSTRACT The present invention relates to process for the preparation of tofacitinib and intermediates thereof.

The present invention relates to a novel process for the preparation of anacetrapib. The present invention also relates to novel intermediate or its salt and its use in the preparation of anacetrapib.

The present invention provides various forms of ivacaftor and processes thereof.

The present invention provides a process for preparation of fingolimod, a compound of Formula I or a pharmaceutically acceptable salt thereof, free of regioisomeric impurity compound of Formula IA

The present invention relates to an oral stable pharmaceutical composition of nitroglycerin. Particularly, the invention is directed towards making a stable sublingual composition of nitroglycerin. This invention aims at improving the stability of the compositions containing nitroglycerin in terms of the uniformity ...

The present invention relates to pharmaceutical composition comprising saxagliptin or its pharmaceutically acceptable salts thereof in an intimate contact with the excipients in the core.

The present invention provides process for the preparation of anagliptin and intermediates thereof.

The present invention relates to a process for the preparation of ticagrelor and pharmaceutically acceptable salts thereof.

Present invention provides a delayed release capsule comprising; a core containing dexlansoprazole or pharmaceutically acceptable salt thereof, alkaline agent and at least one pharmaceutically acceptable carrier, a subcoat of water soluble film forming polymers; wherein about 0 to 50 % of the subcoated core, is coat...

An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s). ...

The present invention relates to modified release pharmaceutical composition comprising. O-desmethylvenlafaxine succinate less than 8.5% by weight of the composition.

The present invention relates to an improved process for the preparation of fosaprepitant and salt thereof.

The present invention relates to the pharmaceutical composition comprising a solid solution of aprepitant or pharmaceutically acceptable salts thereof and water insoluble inert pharmaceutical carrier.

The present invention relates to cyclopentane pyrimidine compounds, a process for their preparation and their use as intermediate compounds in the preparation of ticagrelor.

The present invention relates to a novel process for the preparation of alogliptin.

The present invention relates to a process for the preparation of (S)-(+)-10,11-dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide,(eslicarbazepine), (S)-(-)-10-(acetyloxy)-10,11-dihydro-5H- dibenz[b,f|-azepine-5-carboxamide (eslicarbazepine acetate) and novel compounds that may be useful intermediates in t...

The present invention relates to the pharmaceutical compositions comprising amorphous asenapine maleate and a process for preparing the same.

The present invention provides a process for the preparation of milnacipran intermediate and its use in the preparation of pure milnacipran

The present invention relates to one-pot process for the preparation of saxagliptin monohydrate.

ABSTRACT The present invention provides a process for the preparation of dronedarone and pharmaceutically acceptable salts thereof. The present invention further provides a novel amorphous form of dronedarone hydrochloride, and a process for its preparation.

NA

Disclosed herein a premix comprising saxagliptin or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.

ABSTRACT the process comprising deprotecting a compound of Formula II The present invention provides a process for the preparation of linagliptin, a compound of Formula I, wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phtha...

Disclosed herein a stable pharmaceutical composition comprise a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.

The present invention provides a process for the preparation of retigabine, its intermediate compounds and pharmaceutically acceptable salts thereof.

The present invention relates to process for the preparation of crystalline etoricoxib.

The present invention provides a process for the preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds. The present invention -further provides a process for the preparation of 3'-{N'-[l-(3,4-dimethylphenyl)-3-methyl-5-oxo-1.5-dihydro-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxyli...

The present invention provides a process for the preparation of dabigatran etexilate, a compound of Formula I or a salt thereof Formula I in a purity of at least 99.0% and wherein the level of compound of formula X and XV is less than 0.15% relative to the amount of dabigatran etexilate, a compound of Formula I...

The present invention provides a process for the preparation of vilazodone, its intermediate compounds and pharmaceutically acceptable salts thereof. The present invention also provides solvates of vilazodone hydrochloride and processes for their preparation. The present invention further provides a process for the ...

The present invention relates to stable pharmaceutical suspension comprising atovaquone wherein agglomerations of atovaquone particles have not been observed on shelf life.

The present invention relates to a novel process for preparation of telaprevir.

The present invention relates to processes for the preparation of indiplon and its polymorphic mixtures.

The present invention relates to processes for the preparation of bosentan and compounds that can be used as structurally novel intermediates for the synthesis thereof, and a pharmaceutical composition of the same.

The present invention relates to a process for the preparation of 3-(2-chloroethyl0-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one and its use in the synthesis of paliperidone.

The present invention relates to amorphous form of bazedoxifene acetate and a process for the preparation thereof.

Provided is amorphous bupropion hydrobromide, processes for the preparation thereof, and pharmaceutical compositions therewith.

The present invention relates to crystalline form of prasugrel hydrobromide and process for its preparation.

The present invention relates to solid state chemistry of 1-(2-[4-(4-methoxy-3,4-dihydronaphthalene-1-yl)phenoxy]ethy) pyrrolidine, aprocess for its prepatation and its use as an intermediate in the synthesis of lasofoxifene.

ABSTRACT: A Process for the preparation of 5-"armno-4-cyano-2-(methoxycarbonyl)-3-thiopheneacetic acid methyl ester of a compound formula III wherein Rj"and R2 represents substituted or unsubstituted linear or branched C1-C6 alkyl group or C3:C12 cyclic group and further use of compound formula III for preparation ...

The present invention relates to an extended release (ER) pharmaceutical composition comprising a pharmaceutically acceptable salt of propafenone, and more particularly propafenone hydrochloride (HCI), wherein the propafenone salt has a density less than I.

The present invention relates to processes for the preparation of propargylated aminoindans or their pharmaceutically acceptable salts and pharmaceutical compositions of the same. The present invention relates to preparation of a compound of formula I wherein R1 = H or comprising: a) reacting an indanone...

A PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

An anhydrous, non-solvated crystalline Zofenopril calcium

The present invention provides novel solid milnacipran in crystalline form and a process for its preparation. The present invention also provides a process for the preparation of milnacipran hydrochloride from the novel solid crystalline milnacipran.

The present invention relates to a process for the preparation of liothyronine and its pharmaceutically acceptable salts thereof and a pharmaceutical composition comprising the same.

The present invention provides, a topical pharmaceutical composition comprising herapeutically effective amounts of vitamin D or vitamin D analogues, corticosteroid and a straight chain C6-C28 fatty alcohol.

The present invention relates to modified release pharmaceutical compositions comprising Bupropion Hydrobromide and method of preparation thereof.

The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and water soluble and/or gellable polymer and optionally an enteri...

The present invention relates to pharmaceutical composition comprising Telmisartan and Amlodipine, or pharmaceutically acceptable salts thereof, and to the process of preparation thereof.

The present invention provides a novel process for preparation of N,N-dimethyl-5-(lH-l,2,4-triazol-l-ylrnethyl)-lH-indole-3-ethanamine (Rizatriptan) and intermediates thereof. The present invention also provides a process for preparation of Rizatriptan benzoate. 20

The present invention relates to a process for the preparation of 2. 3-diaryl-5-substituted pyridines, compounds of formula I. The present invention also relates to novel compounds of formula II, and a process for the preparation thereof.

The present invention provides a stable pharmaceutical composition comprising eszopiclone, of median particle size not more than 40 µm.

An amorphous form of Aprepitant and a process for its preparation is provided. Also provided aremixtures of polymorph Forms I and II of Aprepitant and a process for the preparation thereof.

The present invention relates to a controlled release pharmaceutical composition of acetazolamide and pharmaceutical salts thereof, with one or more release controlling material, and to a process for preparing the same.

The present invention relates to an unsolvated form of ranelic acid and the process for the preparation thereof.

The present invention relates to modified release pharmaceutical composition comprising O-desmethylvenlafaxine succinate less than 27% by weight of the composition.

The present invention relates to a process for the preparation of prasugrel, its intermediates, and pharmaceutically acceptable salts and pharmaceutical compositions thereof.

The present invention provides a process for purification of diacerein, compound of Formula I, the process comprising a. reacting diacerein, compound of Formula I with a silylating agent to form a compound of Formula II, silylated diacerein wherein R is alkyl; and b. deprotecting compound of Formula II, s...

The present invention provides a process for preparation of racemic voriconazole in a single reaction vessel. The present invention also provides a process for preparation of voriconazole using racemic voriconazole and the process of making it therewith.

The present invention provides a process for the preparation of paliperidone palmitate comprising reacting paliperidone with palmitic acid or its derivative in the presence of a mixture of an organic base and an inorganic base.

The present invention provides amorphous rosuvastatin calcium having a degree of crystallinity less than about 5% and process for preparation thereof.

The present invention relates to a pharmaceutical composition comprising Dronedarone hydrochloride and at-least one pharmaceutically acceptable excipient wherein the pharmaceutically acceptable excipient is not a surfactant.

The present invention relates to a bilayer pharmaceutical composition comprising telmisartan and hydrochlorothiazide, wherein the telmisartan layer is free from surfactant and hydrochlorothiazide layer does not contain a disintegrant.

The present invention relates to an enteric coated tablet comprising acicular mycophenolate sodium in an amount of 35% to 45 % by weight of the tablet and at-least a pharmaceutically . acceptable excipient comprising at least a diluent preferably anhydrous lactose present in the intra-granular and extra-granular por...

The present invention relates to process for the preparation of vildagliptin.

The present invention provides a process for the preparation and purification of apixaban.

The present invention relates to process for the preparation of rivaroxaban.

The present invention relates to controlled release composition comprising oxcarbazepine or pharmaceutically acceptable salts thereof and process of preparation thereof.

The present invention relates to a stable pharmaceutical composition comprising Eprosartan mesylate substantially in the anhydrous form and at-least one pharmaceutically acceptable carrier. It also provides a process of preparing the stable pharmaceutical composition comprising Eprosartan mesylate substantially in t...

The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.

The present invention relates to a process for the preparation of esomeprazole magnesium, specifically, esomeprazole magnesium containing R-isomer greater than about 0.1% by wt; and pharmaceutical compositions thereof

The present invention relates to process for the preparation of rivaroxaban or intermediates thereof.

A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same.

The present invention relates to process for preparation of roflumilast.

The present invention provides garenoxacin mesylate crystalline form characterized by an X-ray powder diffraction pattern with peaks at about 13.77, 20.54, 21.50, 21.77, 22.12 and 23.90 ± 0.2 °θ.